<DOC>
	<DOCNO>NCT00976976</DOCNO>
	<brief_summary>Despite improvement surgical resection primary curative treatment gastric cancer , 70 % patient stage IIIB IV disease undergo radical primary tumor resection relapse die within 5 year . Therefore , urgent need improve treatment gastric cancer population . Recently report phase III study compare capecitabine/cisplatin ( XP ) versus 5-FU/cisplatin ( FP ) , XP show good activity tolerability compare FP . To improve treatment outcome XP chemotherapy , investigator perform phase I-II study docetaxel , capecitabine cisplatin advance gastric cancer ( AGC ) . Phase I-II study docetaxel , capecitabine cisplatin first-line chemotherapy advance gastric cancer ( Kang et al , Proc Am Soc Clin Oncol 22,328.2003 ) . The docetaxel/capecitabine/cisplatin ( DXP ) chemotherapy highly active 1st-line chemotherapy AGC . These finding experience encourage investigator design adjuvant trial DXP chemotherapy patient resect gastric cancer . The aim study assess efficacy safety adjuvant DXP patient population .</brief_summary>
	<brief_title>Adjuvant Chemotherapy With Docetaxel , Capecitabine Cisplatin Patients With Advanced Gastric Cancer</brief_title>
	<detailed_description>Previous phase II study docetaxel , capecitabine cisplatin , total 40 pt measurable disease , median 6 cycle chemotherapy , 4 confirm complete response ( CRs ) 23 confirm partial response ( PRs ) , overall response rate 67.5 % ( 95 % confidence interval , 52.7 ~ 82.3 ) intention-to-treat analysis . Ten patient underwent surgical resection 4 ~ 9 cycle chemotherapy . Four pathologic CRs identify . With median follow-up 14 month ( range , 1 28 ) , median time progression 7.7 month , median overall survival 16.9 month . The DXP chemotherapy highly active 1st-line chemotherapy AGC ( Kang et al , Proc Am Soc Clin Oncol 22,328.2003 ) .</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>Histologically cytologically document gastric adenocarcinoma Age 18 70 Eastern Cooperative Oncology Group ( ECOG ) performance status 01 Pathologic stage IIIB IV complete resection ( R0 resection ) Other tumor type adenocarcinoma R1 R2 resection Presence distant metastasis Gastric outlet obstruction intestinal obstruction Evidence gastrointestinal bleeding Other serious illness medical condition</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Resected advanced gastric cancer stage IIIB IV</keyword>
</DOC>